Trial Outcomes & Findings for Treatment of Early Nasal Polyposis With Topical Triamcinolone (NCT NCT01222871)
NCT ID: NCT01222871
Last Updated: 2018-06-28
Results Overview
nasal endoscopic exam findings at 2 weeks, 6 weeks and 12 weeks were not collected from any participant.
TERMINATED
PHASE1/PHASE2
1 participants
2 weeks, 6 weeks, 12 weeks were not collected from any participant.
2018-06-28
Participant Flow
One subject enrolled but study was terminated and subject did not start the study.
Participant milestones
| Measure |
Triamcinolone
Nasopore Triamcinolone soaked sponge
|
Control
Saline soaked sponge
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Treatment of Early Nasal Polyposis With Topical Triamcinolone
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 2 weeks, 6 weeks, 12 weeks were not collected from any participant.Population: No participant started because study was terminated.
nasal endoscopic exam findings at 2 weeks, 6 weeks and 12 weeks were not collected from any participant.
Outcome measures
Outcome data not reported
Adverse Events
Triamcinolone
Saline Soaked Sponge
Control
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place